Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone Hydrochloride (HCI) tablets USP, 5 mg, 15 mg and 30 mg, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the generic version of Xanodyne's Roxicodone, a treatment for moderate to severe pain.

Oxycodone HCI tablets had US sales of approximately $325 million for the 12 months ending March 31, 2011, according to IMS Health.

Currently, Mylan has 167 ANDAs pending FDA approval representing $100.3 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending December 31, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories.